We would like to thank Sookaromdeel and Wiwanitkit for their interest in our paper and for taking the time to express their opinion (1). Sahin et al. showed as BNT162b2 mRNA vaccine induces robust and protective humoral and cellular responses to SARS-CoV-2 spike protein (2). While immunocompetent individuals have detectable antibodies after the second vaccination, combined analysis with cellular immunity is superior in identifying vaccine responders among post-transplant individuals (3).
Reply